Formulations of (+)-2-[1-(3-ethoxy-4- methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
AssigneeAmgen Inc.
InventorsSreenivas S. Bhat, Michael T. Kelly
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and single unit dosage forms of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate thereof, are provided herein. Also provided are methods of treating, managing, or preventing various diseases or disorders.
Claims16
-26. (canceled)
A method of treating a disease or disorder selected from the group consisting of psoriasis, arthritis, dermatitis, acne, dermatomyositis, ulcerative colitis, Behcet's disease, Crohn's disease, sarcoidosis, uveitis, rosacea, and lichen planus, comprising administering to a patient in need thereof a pharmaceutical composition in the form of an oral tablet, the pharmaceutical composition comprising:
- a) a core composition, wherein the core composition comprises Compound A:
- or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, and a lubricant, wherein the filler comprises i) lactose monohydrate in an amount of 50% to 65% by weight of the total core composition and ii) cellulose in an amount of 15% to 40% by weight of the total core composition, and
- b) a coating formulation comprising polyvinyl alcohol.
Dependencies are inferred from the claim text.